Indication
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Medicine details
- Medicine name:
- garadacimab (Andembry)
- SMC ID:
- SMC2912
- Pharmaceutical company
- CSL Behring
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 01 September 2026